Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer
November 02 2016 - 8:00AM
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology
company specializing in the characterization and engineering of
complex drugs, today announced the appointment of Scott M. Storer
as Senior Vice President and Chief Financial Officer. Mr. Storer is
expected to begin at Momenta on November 28, 2016 and will replace
Momenta’s current Chief Financial Officer, Rick Shea, who will be
retiring. Mr. Storer will report directly to Craig Wheeler,
Momenta’s President and Chief Executive Officer, and will serve as
a member of the Executive Committee.
“I am very pleased to have Scott join Momenta.
He has a great track record across his 20 years with Baxter and
Baxalta, and I believe his expertise in financial planning and
leading global strategic growth initiatives and operations will
benefit Momenta tremendously,” said Craig Wheeler, President and
CEO, Momenta Pharmaceuticals. “With the addition of Scott’s
leadership, I look forward to continuing to advance the development
and commercialization of our robust portfolio of biosimilar and
novel drug candidates.”
Prior to joining Momenta, Mr. Storer was Senior
Vice President, Finance at Baxalta, Inc. following its spin-out
from Baxter International in July 2015. Previously, Mr. Storer held
several positions with Baxter, most recently serving as Vice
President of BioScience Finance where he provided financial
leadership, internal controls and business partnership to the
BioScience US commercial organization, global manufacturing,
R&D, business development and all support functions. Before
that he held positions of increasing responsibility at several of
Baxter’s international finance divisions. Mr. Storer began his work
at Baxter as a financial analyst in 1997. He received a Master’s in
Business Administration from Northwestern University’s Kellogg
School of Management and a Bachelor of Science degree in business
administration from the University of Colorado at Boulder.
About MomentaMomenta
Pharmaceuticals is a biotechnology company specializing in the
detailed structural analysis of complex drugs and is headquartered
in Cambridge, MA. Momenta is applying its technology to
the development of generic versions of complex drugs, biosimilar
and potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does
not form a part of this press release.
Our logo, trademarks, and service marks are the
property of Momenta Pharmaceuticals, Inc. All other trade names,
trademarks, or service marks are property of their respective
owners.
Forward Looking Statements
Statements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, are forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, including but not limited to statements about Mr. Storer’s
expected start date and the expected benefits from his service to
the Company. Forward-looking statements may be identified by words
such as "anticipate," "believe," "continue," "could," "hope,"
"target," "project," "goal," "objective," "guidance," "plan,"
"potential," "predict," "might," "estimate," "expect," "intend,"
"may," "seek", "should," "will," "would," "look forward" and other
similar words or expressions, or the negative of these words or
similar words or expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors,
including those referred to under the section "Risk Factors" in the
Company's Quarterly Report on Form 10-Q for the quarter ended June
30, 2016, filed with the Securities and Exchange Commission, as
well as other documents that may be filed by the Company from time
to time with the Securities and Exchange Commission. As a result of
such risks, uncertainties and factors, the Company's actual results
may differ materially from any future results, performance or
achievements discussed in or implied by the forward-looking
statements contained herein. The Company is providing the
information in this press release as of this date and assumes no
obligations to update the information included in this press
release or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
INVESTOR CONTACT:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024